AAKP Patient Impact Statement: FDA APPROVAL OF KERENDIA TO HELP SLOW KIDNEY DISEASE AND FAILURE ASSOCIATED WITH TYPE 2 DIABETES
PATIENT IMPACT STATEMENT: FDA APPROVAL OF KERENDIA TO HELP SLOW KIDNEY DISEASE AND FAILURE ASSOCIATED WITH TYPE 2 DIABETES WASHINGTON, D.C. – The American Association of Kidney Patients, the largest kidney patient consumer and caregiver organization in the nation, today issued the following statement regarding the recent approval by the…